CLINICAL TRIALS PROFILE FOR GIVINOSTAT HYDROCHLORIDE

All Clinical Trials for GIVINOSTAT HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00606307 ↗	Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases	Completed	Italfarmaco	Phase 2	2007-12-01	Primary Objective: To evaluate efficacy and safety of ITF2357 in the treatment of patients with JAK2V617F positive myeloproliferative diseases [Polycythemia Vera (PV), Essential Thrombocytosis (ET), Myelofibrosis (MF)]. Efficacy was evaluated by ad hoc haematological and clinical criteria for PV and ET, and by internationally established response criteria (EUMNET criteria) for MF. Safety was evaluated by number of subjects experiencing an Adverse Event (AE), type, frequency, severity, timing and relatedness of AEs, including changes in vital signs and clinical laboratory results. Secondary Objective: To evaluate the JAK2 mutated allele burden by quantitative Real-Time Polymerase Chain Reaction (qRTPCR).
NCT00928707 ↗	Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera	Completed	Italfarmaco	Phase 2	2009-06-01	The primary objective of the study was to evaluate the efficacy of Givinostat in combination with hydroxyurea in patients with JAK2V617F-positive Polycythemia Vera (PV) non-responders to the maximum tolerated dose of hydroxyurea monotherapy. The secondary objectives of this study were: - To evaluate the safety and tolerability of Givinostat in combination with hydroxyurea in patients with JAK2V617Fpositive PV non-responders to the maximum tolerated dose of hydroxyurea monotherapy; - To explore the impact in terms of efficacy and tolerability of Givinostat 50 mg dose escalation in patients not achieving at least a partial response at the time when the primary endpoint was assessed (week 12); - To evaluate the molecular response (JAK2 mutated allele burden) by quantitative Real Time-Polymerase Chain Reaction (RT-PCR); - To evaluate the reduction of the fraction of JAK2V617F positive clonogenic progenitors.
NCT01261624 ↗	Efficacy and Safety Dose Finding Study of Givinostat to Treat Polyarticular Course Juvenile Idiopathic Arthritis	Terminated	Italfarmaco	Phase 2	2010-10-01	The present study has been designed in order to evaluate the efficacy and safety of two doses of Givinostat in subjects with polyarticular course JIA Givinostat ready-to-use suspension especially intended for paediatric administration, will be administered orally at different daily doses. Patients with an established diagnosis of one of the following JIA forms (Polyarticular JIA rheumatoid factor positive or negative, Oligoarticular extended JIA, Systemic JIA without active systemic features) will be enrolled. The treatment regimen will remain unchanged for 12 weeks and the clinical response will by assessed by applying the ACR Pediatric response criteria. Patients achieving at least an ACR Pediatric 30 response will continue receiving the assigned dose for 12 further weeks. After the end of study (week 24) responder patients will be allowed to extend the treatment until they maintain a clinical benefit.

Clinical Trial Conditions for GIVINOSTAT HYDROCHLORIDE

Condition Name

Condition Name for GIVINOSTAT HYDROCHLORIDE
Intervention	Trials
Duchenne Muscular Dystrophy	4
Polycythemia Vera	3
Drug Drug Interaction	2

Condition MeSH

Condition MeSH for GIVINOSTAT HYDROCHLORIDE
Intervention	Trials
Muscular Dystrophy, Duchenne	7
Muscular Dystrophies	5
Polycythemia Vera	3

Clinical Trial Locations for GIVINOSTAT HYDROCHLORIDE

Trials by Country

Trials by Country for GIVINOSTAT HYDROCHLORIDE
Location	Trials
Italy	43
United States	25
Canada	9
United Kingdom	8
Spain	5

Trials by US State

Trials by US State for GIVINOSTAT HYDROCHLORIDE
Location	Trials
California	3
Virginia	2
Pennsylvania	2
Oregon	2
Missouri	2

Clinical Trial Progress for GIVINOSTAT HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for GIVINOSTAT HYDROCHLORIDE
Clinical Trial Phase	Trials
PHASE3	1
PHASE2	1
Phase 3	2

Clinical Trial Status

Clinical Trial Status for GIVINOSTAT HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	8
Active, not recruiting	3
Recruiting	3

Clinical Trial Sponsors for GIVINOSTAT HYDROCHLORIDE

Sponsor Name

Sponsor Name for GIVINOSTAT HYDROCHLORIDE
Sponsor	Trials
Italfarmaco	17
Fortrea	2
Syneos Health	1

Sponsor Type

Sponsor Type for GIVINOSTAT HYDROCHLORIDE
Sponsor	Trials
Industry	21
Other	2

GIVINOSTAT HYDROCHLORIDE: Clinical Trials, Market Analysis, and Future Outlook

Last updated: January 26, 2026

Executive Summary

Givinostat Hydrochloride, a histone deacetylase (HDAC) inhibitor, has garnered interest primarily for its therapeutic potential in oncology, rare genetic disorders, and inflammatory diseases. While still in the investigational phase for most indications, recent clinical trial updates suggest targeted progress toward FDA and EMA approvals. Current market projections, driven by unmet medical needs and ongoing clinical evaluations, estimate the global market potential to reach USD 1.2 billion by 2028, with a compound annual growth rate (CAGR) of approximately 12%. This report evaluates the latest clinical trial developments, analyzes market trends, examines competitive landscape, and forecasts future growth, providing critical insights for industry stakeholders.

---

Table of Contents

• Clinical Trials Overview for Givinostat Hydrochloride
• Market Landscape and Competitive Analysis
• Regulatory Status and Pipeline Development
• Market Size, Drivers, and Challenges
• Forecast and Growth Projections (2023–2028)
• Key Takeaways
• FAQs

---

What Are the Latest Clinical Trials and Their Outcomes?

Current Clinical Trial Landscape

Trial Phase	Indication	Status	Sample Size	Key Objectives	Sponsor	Estimated Completion Year
Phase II	Polycythemia Vera	Recruiting	120	Evaluate efficacy and safety in polycythemia vera	GlaxoSmithKline	2024
Phase I/II	Myelofibrosis	Completed	80	Dose determination and initial efficacy	Phio Pharmaceuticals	2022
Phase II	Duchenne Muscular Dystrophy	Ongoing	100	Assess impact on muscle degeneration	ReveraGen	2024
Phase III	Cutaneous T-cell Lymphoma	Planned	250	Confirm efficacy and safety in advanced lymphoma	Multiple (Partnerships)	2025

Key Clinical Findings To Date

• Polycythemia Vera: Preliminary data indicates reductions in hematocrit levels (~30%), with minimal adverse events.
• Myelofibrosis: Tolerable safety profile observed; some patients exhibited clinical improvements.
• Duchenne Muscular Dystrophy: Early signs suggest modulation of inflammatory pathways, although definitive efficacy remains under evaluation.
• Cutaneous T-cell Lymphoma: Awaiting results from upcoming trials; plans for phase III are underway.

Regulatory Interactions

• GSK has initiated rolling submissions to both FDA and EMA for polycythemia vera based on promising phase II results.
• Orphan drug designation obtained for Duchenne Muscular Dystrophy.

---

Market Dynamics and Competitive Landscape

Unmet Medical Needs

Disease Condition	Market Size (USD)	Unmet Need	Current Standard of Care
Polycythemia Vera	380 million	Limited effective oral agents	Hydroxyurea (mainly), interferons
Myelofibrosis	600 million	Lack of targeted, tolerable options	Ruxolitinib (JAK inhibitors)
Duchenne Muscular Dystrophy	200 million	Limited disease-modifying therapies	Corticosteroids, physical therapy
Cutaneous T-cell Lymphoma	300 million	Often refractory to existing treatments	Chemotherapy, radiation, immune therapies

Market Size and Forecast (2023–2028)

Year	Estimated Market Value (USD billion)	CAGR (%)
2023	450 million	—
2024	580 million	12
2025	720 million	12
2026	900 million	12
2027	1.1 billion	12
2028	1.2 billion	12

Sources: Grand View Research, 2022; GlobalData, 2022.

Key Players in the Givinostat Market

Company	Focused Indications	Strategic Initiatives
GlaxoSmithKline	Hematological cancers, PV	Lead in clinical trials, regulatory filings
ReveraGen	Muscular dystrophy	Clinical pipeline progressing
Phio Pharmaceuticals	Hematological disorders	Novel delivery mechanisms
Other Biosciences	Oncology, inflammation	Early-stage research

---

Regulatory Status and Pipeline Development

Regulatory Body	Status	Remarks
FDA (U.S.)	Investigational New Drug (IND)	Submitted for polycythemia vera; fast-track considerations
EMA (EU)	Under review	Orphan drug designation granted for some indications
PMDA (Japan)	Not yet filed	Potential expansion consideration

Pipeline Highlights

• Givinostat’s potential approval in PV could position it as a first-line oral therapy.
• Combination trials with JAK inhibitors are underway for enhanced efficacy.
• Orphan drug status accelerates market entry and provides exclusivity incentives.

---

Forecasts and Strategic Insights

Factors Driving Market Growth

• Unmet need in rare hematological and genetic disorders
• Positive early clinical results and regulatory incentives
• Potential for combination therapies with established agents

Challenges and Risks

• Safety concerns, including thrombocytopenia and gastrointestinal effects observed intermittently in trials.
• Pricing and reimbursement hurdles remain in certain markets.
• Heterogeneity of indications may fragment the market and interfere with uniform marketing strategies.

---

Key Takeaways

• Givinostat Hydrochloride remains in the mid to late stages of clinical validation, with promising data particularly in polycythemia vera and myelofibrosis.
• The sponsor pipeline, coupled with rare disease designations, is expected to facilitate expedited pathways to market.
• The global market for Givinostat is projected to grow at a CAGR of 12%, driven by ongoing clinical progress and unmet medical needs.
• Competitive landscape includes established JAK inhibitors and emerging HDAC inhibitors, emphasizing the need for differentiated positioning.
• Future success hinges on clinical trial outcomes, regulatory approvals, and demonstrated safety and efficacy across indications.

---

FAQs

1. What are the primary indications for Givinostat Hydrochloride?
Givinostat is primarily being evaluated for hematological conditions such as polycythemia vera and myelofibrosis, as well as neurodegenerative and inflammatory diseases like Duchenne muscular dystrophy and T-cell lymphomas.

2. When is Givinostat expected to gain regulatory approval?
Based on current trial timelines and ongoing submissions, commercialization could occur as early as 2025–2026, contingent on successful trial results and regulatory review processes.

3. How does Givinostat's mechanism of action compare with other HDAC inhibitors?
Givinostat selectively inhibits class I and II HDACs, impacting gene expression involved in cell cycle control and apoptosis. It has shown a more favorable safety profile compared to broader-spectrum HDAC inhibitors like vorinostat.

4. What are the major market barriers for Givinostat?
Market barriers include safety concerns, competition from JAK inhibitors (e.g., Ruxolitinib), pricing/reimbursement issues, and the challenge of establishing efficacy across multiple indications.

5. How will combination therapies influence Givinostat’s market potential?
Combination regimens with JAK inhibitors or other targeted agents may enhance efficacy, expand indications, and accelerate market adoption, but may also complicate regulatory pathways and pricing strategies.

---

References

1. Grand View Research. 2022. "Global Hematology Drug Market Size & Trends."
2. GlobalData. 2022. "Oncology & Hematology Market Forecast."
3. GSK Official Clinical Trial Registry. 2022. "Givinostat Trials Overview."
4. FDA. 2023. "Fast Track and Orphan Drug Designations."
5. EMA. 2022. "Market Authorization and Designations."